The stock of Alzamend Neuro Inc (ALZN) has seen a -7.05% decrease in the past week, with a -7.05% drop in the past month, and a -32.56% decrease in the past quarter. The volatility ratio for the week is 7.24%, and the volatility levels for the past 30 days are at 7.62% for ALZN. The simple moving average for the past 20 days is -11.07% for ALZN’s stock, with a -72.91% simple moving average for the past 200 days.
Is It Worth Investing in Alzamend Neuro Inc (NASDAQ: ALZN) Right Now?
The 36-month beta value for ALZN is at -0.03. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALZN is 4.24M, and currently, shorts hold a 5.39% of that float. The average trading volume for ALZN on November 07, 2024 was 1.72M shares.
ALZN) stock’s latest price update
The stock of Alzamend Neuro Inc (NASDAQ: ALZN) has decreased by -11.59 when compared to last closing price of 1.64.Despite this, the company has seen a loss of -7.05% in its stock price over the last five trading days. benzinga.com reported 2024-08-19 that Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.
Analysts’ Opinion of ALZN
Many brokerage firms have already submitted their reports for ALZN stocks, with Ascendiant Capital Markets repeating the rating for ALZN by listing it as a “Buy.” The predicted price for ALZN in the upcoming period, according to Ascendiant Capital Markets is $8 based on the research report published on October 01, 2021 of the previous year 2021.
ALZN Trading at -18.40% from the 50-Day Moving Average
After a stumble in the market that brought ALZN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.75% of loss for the given period.
Volatility was left at 7.62%, however, over the last 30 days, the volatility rate increased by 7.24%, as shares sank -9.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.91% lower at present.
During the last 5 trading sessions, ALZN fell by -7.05%, which changed the moving average for the period of 200-days by -83.60% in comparison to the 20-day moving average, which settled at $1.6305. In addition, Alzamend Neuro Inc saw -83.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALZN starting from AULT MILTON C III, who purchase 75 shares at the price of $2.75 back on Aug 06 ’24. After this action, AULT MILTON C III now owns 77,268 shares of Alzamend Neuro Inc, valued at $206 using the latest closing price.
AULT MILTON C III, the Director of Alzamend Neuro Inc, purchase 25 shares at $3.74 during a trade that took place back on Jul 31 ’24, which means that AULT MILTON C III is holding 77,193 shares at $93 based on the most recent closing price.
Stock Fundamentals for ALZN
Current profitability levels for the company are sitting at:
- -96.89 for the present operating margin
- 0.33 for the gross margin
The net margin for Alzamend Neuro Inc stands at -97.15. The total capital return value is set at 6.08. Equity return is now at value -4408.31, with -344.10 for asset returns.
Currently, EBITDA for the company is -9.89 million with net debt to EBITDA at 0.16. When we switch over and look at the enterprise to sales, we see a ratio of 69.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.49.
Conclusion
In conclusion, Alzamend Neuro Inc (ALZN) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
